The dismal results of the AstraZeneca vaccine trial, released on Sunday, are a "reality check", says Wits professor Shabir Madhi, after hopes were raised last year when other vaccines proved to be 95% effective against Covid-19.

Madhi was speaking after it emerged on Sunday that the AstraZeneca-Oxford vaccine did not prevent mild disease in a group of young and healthy people. This was due to a new variant 501Y.V2, first detected in SA. The trials measured "disease" as a single symptom of cough, fever or sore throat...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now